DBV Technologies SA - American (DBVT) AI Stock Analysis

• Market Cap: $266.68M
• Dividend Yield: N/A
• Average Volume (3M): 840.11K
• Price to Earnings (P/E): ―
• Beta (1Y): -0.30
• Revenue Growth: N/A
• EPS Growth: -38.74%
• Country: US
• Employees: 109
• Sector: Healthcare
• Sector Strength: 50
• Industry: Biotechnology
• EPS (TTM): -0.26
• Shares Outstanding: 27,389,774
• 10 Day Avg. Volume: 101,573
• 30 Day Avg. Volume: 840,109
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): 0.00
• Price to Cash Flow (P/CF): 0.00
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: 0.48
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: -30.29
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: $13.00
• Price Target Upside: 32.11% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 2

DBV Technologies SA's stock score is driven by financial instability due to declining revenues and negative returns, which are partially offset by strong recent technical momentum and positive corporate developments. The substantial funding secured for the Viaskin Peanut program is a significant positive, but the stock's valuation remains a concern due to ongoing losses.

Positive Factors

Market Opportunity

Given the regulatory clarity, investors now have the goal line for Viaskin Peanut in sight, which is relatively derisked, and can start evaluating the commercial opportunity which could be ~$2B+ annually.

Product Efficacy

Viaskin Peanut provides clinically relevant protection against accidental exposures to peanut protein, with physicians expecting to prescribe it to approximately 30% of their eligible patients.

Regulatory Alignment

The FDA confirms requirements for Viaskin Peanut’s accelerated approval pathway in toddlers with DBV Technologies targeting BLA submissions in toddlers and children.

Negative Factors

Clinical Risk

The VITESSE trial in peanut-allergic children (4–7 years) represents the last major clinical risk for Viaskin, with the Phase 3 trial fully enrolled and using a modified patch informed by previous studies.

Financial Concerns

DBVT ended the year with $33M in cash which management said is sufficient to fund operations into April, so management will need to bring in capital immediately.

DBV Technologies SA - American Business Overview & Revenue Model

Company Description

DBV Technologies SA - American (DBVT) is a clinical-stage biopharmaceutical company that specializes in the development of innovative products for the treatment of food allergies and other immunological disorders. The company's core technology, Viaskin, is a proprietary platform that delivers biologically active compounds to the immune system through intact skin. DBV Technologies primarily focuses on its lead product candidate, Viaskin Peanut, which is designed to treat peanut allergies in children and adults.

How the Company Makes Money

DBV Technologies makes money by developing and potentially commercializing its pipeline of products based on the Viaskin platform. The company's revenue model is centered around the successful development, approval, and eventual commercialization of its lead product, Viaskin Peanut, as well as other potential products in its pipeline. DBV Technologies may also generate revenue through strategic partnerships, research and development collaborations, and licensing agreements with other pharmaceutical companies. These partnerships could potentially provide upfront payments, milestone payments, and royalties on product sales, contributing to the company's earnings.

DBV Technologies SA - American Financial Statement Overview

Summary

DBV Technologies SA is facing financial instability due to declining revenues and ongoing operational losses. While the balance sheet shows low leverage, cash flow issues and negative returns highlight significant challenges that need to be addressed for improved financial stability.

Income Statement

DBV Technologies SA has experienced a significant decline in revenue from $15.73 million in the previous year to $2.57 million in the TTM (Trailing-Twelve-Months), indicating a revenue contraction. The company also posted negative EBIT and net income margins, reflecting ongoing operational challenges and high expenses relative to revenue. Despite gross profit being positive, the net profit margin remains negative.

Balance Sheet

The company maintains a relatively low debt-to-equity ratio, indicating limited leverage which is a positive aspect. However, the return on equity is negative due to the net losses, and the equity ratio has declined, indicating reduced financial stability. This suggests potential challenges in maintaining equity levels without external financing.

Cash Flow

DBV Technologies SA reported a negative free cash flow, with a deterioration in operating cash flow compared to the previous year. The free cash flow to net income ratio is negative, indicating cash flow issues. Despite a slight improvement in financing cash flow, the overall cash flow situation points to liquidity challenges.

Breakdown
Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement		Total Revenue
2.57M	15.73M	4.80M	5.71M	0.00
	Gross Profit
-4.26M	15.73M	-15.50M	-3.57M	-18.82M
	EBIT
-120.74M	-76.43M	-96.63M	-98.61M	-194.80M
	EBITDA
-111.18M	-87.46M	-76.68M	-79.77M	-162.74M
	Net Income Common Stockholders
-113.92M	-72.73M	-96.30M	-97.81M	-195.68M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
32.46M	141.37M	209.20M	77.30M	240.80M
	Total Assets
65.66M	182.99M	246.50M	146.72M	333.87M
	Total Debt
7.80M	6.55M	10.02M	18.69M	40.63M
	Net Debt
-24.66M	-134.81M	-199.18M	-58.61M	-200.17M
	Total Liabilities
38.27M	42.80M	52.00M	47.45M	81.87M
	Stockholders Equity
27.39M	140.19M	194.50M	99.27M	252.01M
Cash Flow		Free Cash Flow
-106.81M	-80.33M	-56.45M	-109.16M	-206.48M
	Operating Cash Flow
-104.47M	-79.65M	-55.70M	-108.24M	-203.10M
	Investing Cash Flow
-757.00K	-808.00K	-100.00K	-433.00K	―
	Financing Cash Flow
587.00K	6.77M	194.10M	274.00K	183.40M

DBV Technologies SA - American Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 9.84
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For DBVT, the sentiment is Positive. The current price of 9.84 is above the 20-day moving average (MA) of 8.77, above the 50-day MA of 6.72, and above the 200-day MA of 4.61, indicating a bullish trend. The MACD of 0.82 indicates Positive momentum. The RSI at 68.25 is Neutral, neither overbought nor oversold. The STOCH value of 80.46 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for DBVT.

DBV Technologies SA - American Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
PLX	56 Neutral	$217.08M	103.80	10.42%	―	-18.47%	-70.64%
DBVT	55 Neutral	$266.68M	―	-198.47%	―	―	-38.74%
Sector *	52 Neutral	$5.17B	3.59	-42.19%	2.82%	15.05%	-0.04%
CDTX	42 Neutral	$247.11M	―	-299.58%	―	-86.28%	-476.70%
ENGN	42 Neutral	$172.81M	―	-44.21%	―	―	―
CRVS	41 Neutral	$228.25M	―	-100.13%	―	―	-71.53%
CRGX	40 Underperform	$189.97M	―	-65.94%	―	―	―

DBV Technologies SA - American Corporate Events

DBV Technologies Secures $306.9M for Viaskin Peanut Program

On March 27, 2025, DBV Technologies announced a private placement agreement to raise up to $306.9 million (€284.5 million) to advance its Viaskin Peanut program. The financing, led by prominent healthcare investors, will support the company’s efforts to submit a Biologics License Application to the FDA and prepare for a potential U.S. launch. The funding will result in a dilution of existing shareholders but reflects strong investor confidence in the Viaskin Peanut patch’s potential impact on treating pediatric peanut allergies.